The Effect of Acute Concurrent Exercise on Inhibitory Control: An Event-related Potential Study

April 16, 2024 updated by: National Taiwan Normal University
The present study aimed to determine the effects of acute concurrent exercise on inhibitory control via behavioral and event-related potential approaches and to examine its potential mediational role on lactate among younger adults. The main questions it aims to answer are: (1) Does acute concurrent exercise improve inhibitory control via behavioral and event-related potential approaches? (2) Does lactate play a potential mediational role in the effect of acute concurrent exercise on inhibitory control?

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The present study aimed to determine the effects of acute concurrent exercise (CE) on inhibitory control via behavioral and event-related potential approaches and to examine its potential mediational role on lactate. Participants were randomly assigned to either a CE, aerobic exercise (AE), or control (CON) group. Participants in the CE group engaged in 12-minutes of AE (40%-59% of heart rate reserve [HRR]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). The AE group participated in 25 minutes of AE (40%-59% HRR). Prior to and following exercise onset, participants in both the CE and AE groups completed a 5-minute warm-up and cool-down. Participants in the CON group read books for 35 minutes. Lactate concentrations were measured at timepoint of 0-, 17-, and 30-minutes relative to the treatment onset. Response time (RT) and accuracy in the Stroop test, as well as P3 amplitudes, were assessed before and after the treatment.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
78

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan, 106
        • Department of Physical Education and Sport Sciences, National Taiwan Normal University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • aged between 20 and 30 years
  • able to exercise without undue risk (i.e., the first seven questions of the Physical Activity Readiness Questionnaire for Everyone [PAR-Q+] were answered "No")
  • right-handed dominance
  • typical or corrected-to-typical eyesight
  • limited physical activity in the previous month (i.e., < 150 minutes/week of moderate-intensity physical activity)

Exclusion Criteria:

  • psychiatric or neurological ailments
  • cardiorespiratory or neuromuscular conditions
  • obese status (body mass index [BMI] > 27 kg/m2)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: concurrent exercise (CE)
Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve [HRR]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
Behavioral: concurrent exercise (CE)
Participants in the concurrent exercise group engaged in 12-minutes of aerobic exercise (40%-59% of heart rate reserve [HRR]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
Experimental: aerobic exercise (AE)
Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve [HRR]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
Behavioral: aerobic exercise (AE)
Participants in the aerobic exercise (AE) group participated in 25 minutes of AE (40%-59% of heart rate reserve [HRR]). Prior to and following exercise onset, participants completed a 5-minute warm-up and cool-down.
No Intervention: control (CON)
Participants in the control group read books for 35 minutes.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Inhibitory control
Time Frame: 30 minutes
Inhibitory control was assessed using a modified computerized version of the Stroop test, which was administered through Neuroscan Stim2 software (Compumedics Neuroscan, Charlotte, NC). The test comprised four blocks, each consisting of 108 trials. Within each block, three types of trials were presented: neutral, congruent, and incongruent. The neutral trial involved displaying a square printed in red, green, or blue color. The congruent trial presented Chinese language prints in corresponding colors and words [i.e., 紅 (RED), 綠 (GREEN), or 藍 (BLUE)]. In contrast, the incongruent trial displayed Chinese language prints in different colors and words [e.g., 紅 (RED) printed in blue color]. Each block included 36 neutral trials, 36 congruent trials, and 36 incongruent trials. Participants were instructed to respond promptly and accurately to the color of the stimulus presented. Subsequently, the mean response time (RT) of correct trials and accuracy for each Stroop condition were examined.
30 minutes

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Blood lactate
Time Frame: Timepoint 1 (prior to the commencement of treatment), Timepoint 2 (17 minutes after the initiation of treatment), and Timepoint 3 (30 minutes after the start of treatment).
Blood lactate levels were assessed using fingertip samples measured with a lactate analyzer (The EDGE, Taipei, Taiwan) at three distinct time points: Timepoint 1 (prior to the commencement of treatment), Timepoint 2 (17 minutes after the initiation of treatment), and Timepoint 3 (30 minutes after the start of treatment).
Timepoint 1 (prior to the commencement of treatment), Timepoint 2 (17 minutes after the initiation of treatment), and Timepoint 3 (30 minutes after the start of treatment).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Taiwan Normal University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Yu-Kai Chang, PhD, Department of Physical Education and Sport Sciences, National Taiwan Normal University
  • Principal Investigator: Ruei-Hong Li, MS, Department of Physical Education and Sport Sciences, National Taiwan Normal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 15, 2021

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 15, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 12, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 17, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 18, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 16, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • PACNL_rueihongli_CE_IC

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise

Clinical Trials on concurrent exercise (CE)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings